1046118-40-4: Atorvastatin Diepoxide Lactone Impurity
It is homozygous or heterozygous familial hypercholesterolemia, mixed dyslipidemia, isolated hypertriglyceridemia, or nonfamilial hypercholesterolemia, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), very-low-density lipoprotein (VLDL-C) and triglycerides.
Additional information on CAS 1046118-40-4
VE007949
1046118-40-4
C33H33FN2O6
572.62 g/mol
Atorvastatin
4-(4-Fluorophenyl)-6-(1-methylethyl)-N, 2-diphenyl-5-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-3, 7-dioxa-5-azatricyclo[4.1.0.02, 4] heptane-1-carboxamide
N/A
McIver, Lindsey A., and Momin S. Siddique. “Atorvastatin.” Nih.gov, StatPearls Publishing, 5 Jan. 2019, http://www.ncbi.nlm.nih.gov/books/NBK430779/. Ramkumar, Satish, et al. “Statin Therapy: Review of Safety and Potential Side Effects.” Acta Cardiologica Sinica, vol. 32, no. 6, Taiwan Society of Cardiology, 2016, pp. 631–39, https://doi.org/10.6515/ACS20160611A.
In-stock
Other products related to atorvastatin
Name of Impurity | Catalogue No. |
---|